Risdiplam Therapy

Risdiplam Therapy is a pharmacotherapeutic approach that belongs to the class of survival motor neuron-2 (SMN2) splicing modulators, distinguished by its administration of the small molecule risdiplam to enhance full-length SMN protein production in patients with spinal muscular atrophy.

42

Publications

2.7K

Citations

577

Authors

168

Institutions

Publications per year

2017–2026

42

Authors

577

  1. KG
    Ksenija Gorni

    Roche (Switzerland), Switzerland

    16 publications · 1.3K citations

    13

    h-index

  2. HK
    Heidemarie Kletzl

    Roche (Switzerland), Switzerland

    14 publications · 1.1K citations

    12

    h-index

  3. RS
    R. Scalco

    University College London, United Kingdom

    12 publications · 1.3K citations

    12

    h-index

  4. GB
    Giovanni Baranello

    Fondazione IRCCS Istituto Neurologico Carlo Besta, Italy

    12 publications · 1.1K citations

    11

    h-index

  5. EM
    Eugenio Mercuri

    Università Cattolica del Sacro Cuore, Italy

    12 publications · 925 citations

    11

    h-index

1–5 of 577

Venues

  1. Neurology

    5 publications · 96 citations

    5

    h-index

  2. Muscle & Nerve

    4 publications · 129 citations

    4

    h-index

  3. Annals of Clinical and Translational Neurology

    ACTN · 2 publications · 74 citations

    2

    h-index

  4. Journal of Neurology

    2 publications · 120 citations

    2

    h-index

  5. Nucleic Acids Research

    2 publications · 71 citations

    2

    h-index

1–5